PTCH1 and ovarian cancer: Malignancies where PTCH1 is wild type—such as in GBM, pancreatic cancer, ovarian cancers etc.—the resultant effect of ligand-driven aberrant activation of Hh-pathway might be “dampened” or “mellowed down” by PTCH1-mediated negative feed-back mechanisms.